Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1922778 | 0.98 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5722167 | 0.90 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL28206303 | 0.79 | CHRNA4 (0.41) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL8553350 | 0.79 | SLC6A4 (0.51) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL4997661 | 0.79 | SLC6A4 (0.41) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL28896790 | 0.76 | CHRM2 (0.60) | CHRM3CHRM2 | |
| SCHEMBL7394452 | 0.76 | KMT2A (0.45) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20555953 | 0.73 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL17506337 | 0.72 | NAPRT (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17796940 | 0.72 | USP30 (0.51) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116813533-A | Lei Fen narasin oxidized impurity and preparation method thereof | 斯坦德药典标准物质研发(湖北)有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-107849014-B | Biphenyl derivative, preparation method and medical application thereof | 四川海思科制药有限公司 | 2021-07-09 | — | — | CN | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20040110229-A1 | Muscarinic receptor antagonists | PNC BANK, NATIONAL ASSOCIATION | 2004-06-10 | — | — | US | disclosed |
| US-6693202-B1 | MULTIBINDING LIGANDS CONTAINING SUCH AS AMINE, AMIDE, ESTER, HYDROXYL, CARBAMATE, UREA AND/OR IMINO FUNCTIONALITY | THERAVANCE, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030087306-A1 | Methods for identifying novel multimeric agents that modulate receptors | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-05-08 | — | — | US | disclosed |
| EP-1086066-A4 | MUSCARINIC RECEPTOR ANTAGONISTS | ADVANCED MEDICINE INC (US) | 2001-08-08 | — | — | EP | disclosed |
| EP-1086065-A1 | COMBINATORIAL SYNTHESIS OF MULTIBINDING LIBRARIES | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1086066-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1086065-A4 | COMBINATORIAL SYNTHESIS OF MULTIBINDING LIBRARIES | ADVANCED MEDICINE INC (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1082289-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1082289-A4 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999066944-A9 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-1999064043-A9 | MUSCARINIC RECEPTOR ANTAGONISTS | ADVANCED MEDICINE INC (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999066944-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999064043-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064032-A1 | COMBINATORIAL SYNTHESIS OF MULTIBINDING LIBRARIES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110229-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | SLC6A2 2407/4885SLC6A4 2310/4885SLC6A3 2378/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | SLC6A2 2407/4885SLC6A4 2310/4885SLC6A3 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.